IE Krop

578 total citations
60 papers, 408 citations indexed

About

IE Krop is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, IE Krop has authored 60 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 21 papers in Cancer Research. Recurrent topics in IE Krop's work include HER2/EGFR in Cancer Research (42 papers), Advanced Breast Cancer Therapies (25 papers) and Cancer Treatment and Pharmacology (21 papers). IE Krop is often cited by papers focused on HER2/EGFR in Cancer Research (42 papers), Advanced Breast Cancer Therapies (25 papers) and Cancer Treatment and Pharmacology (21 papers). IE Krop collaborates with scholars based in United States, France and Spain. IE Krop's co-authors include Shanu Modi, Sandhya Girish, M. Birkner, Jay Tibbitts, Scott N. Holden, H. A. Burris, Patricia LoRusso, M. Beeram, Jennifer Savoie and Eric P. Winer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

IE Krop

58 papers receiving 401 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
IE Krop United States	12	357	191	108	76	73	60	408
Santiago Escrivá-de-Romaní Spain	9	348 1.0×	191 1.0×	124 1.1×	78 1.0×	70 1.0×	30	424
Donggeng Liu China	7	248 0.7×	82 0.4×	145 1.3×	70 0.9×	118 1.6×	15	343
Danai Fimereli Belgium	7	211 0.6×	81 0.4×	67 0.6×	140 1.8×	63 0.9×	10	294
Marie-Pascale Graas Belgium	5	307 0.9×	48 0.3×	183 1.7×	106 1.4×	103 1.4×	8	389
C. M. Schlotter Germany	8	194 0.5×	89 0.5×	57 0.5×	83 1.1×	145 2.0×	22	329
IA Mayer United States	9	236 0.7×	43 0.2×	170 1.6×	66 0.9×	88 1.2×	25	297
Arielle J. Medford United States	8	139 0.4×	38 0.2×	88 0.8×	98 1.3×	50 0.7×	44	247
Elisa Genovesi Italy	4	251 0.7×	123 0.6×	75 0.7×	157 2.1×	23 0.3×	6	289
Ning Liao China	10	184 0.5×	51 0.3×	84 0.8×	128 1.7×	57 0.8×	23	277
Tong Luo United States	5	225 0.6×	41 0.2×	204 1.9×	63 0.8×	119 1.6×	10	312

Countries citing papers authored by IE Krop

Since Specialization

Citations

This map shows the geographic impact of IE Krop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by IE Krop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites IE Krop more than expected).

Fields of papers citing papers by IE Krop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by IE Krop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by IE Krop. The network helps show where IE Krop may publish in the future.

Co-authorship network of co-authors of IE Krop

This figure shows the co-authorship network connecting the top 25 collaborators of IE Krop. A scholar is included among the top collaborators of IE Krop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with IE Krop. IE Krop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rugo, H. S., Eriko Tokunaga, Hiroji Iwata, et al.. (2024). 267MO Pooled analysis of trastuzumab deruxtecan (T-DXd) retreatment (RTx) after recovery from grade (Gr) 1 interstitial lung disease/pneumonitis (ILD). ESMO Open. 9. 103326–103326. 3 indexed citations

Huang, C-Y, Lilja B. Sólnes, Vandana G. Abramson, et al.. (2022). 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026). Annals of Oncology. 33. S623–S624. 1 indexed citations

Hamilton, Erika, Jorge Ramos, Wentao Feng, & IE Krop. (2021). 128TiP HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally-advanced or metastatic breast cancer with and without brain metastases. Annals of Oncology. 32. S76–S76.

Metzger, Otto, Chiara Lambertini, IE Krop, et al.. (2021). 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC). Annals of Oncology. 32. S37–S38. 3 indexed citations

Han, Heon, Lajos Pusztai, Sara A. Hurvitz, et al.. (2021). 259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer. Annals of Oncology. 32. S474–S475. 23 indexed citations

Carey, Lisa A., IE Krop, Jorge Ramos, Wentao Feng, & Erika Hamilton. (2021). 331TiP HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases. Annals of Oncology. 32. S510–S511. 1 indexed citations

André, Fabrice, et al.. (2019). Phase III study of [fam-] trastuzumab deruxtecan vs investigator’s choice in T-DM1-pretreated HER2+ breast cancer. Annals of Oncology. 30. iii63–iii63. 2 indexed citations

Tsurutani, Junji, Toshihiko Doi, Shanu Modi, et al.. (2018). OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S324–S324. 22 indexed citations

Barroso‐Sousa, Romualdo, et al.. (2018). Abstract OT1-02-02: A phase II study of pembrolizumab in combination with palliative radiotherapy for metastatic hormone receptor positive breast cancer. Cancer Research. 78(4_Supplement). OT1–2. 1 indexed citations

10.

Saura, Cristina, Mafalda Oliveira, DA Richards, et al.. (2017). Abstract P6-12-01: Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA. Cancer Research. 77(4_Supplement). P6–12. 2 indexed citations

11.

Tanioka, Maki, Chuanwen Fan, LA Carey, et al.. (2017). Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer. Cancer Research. 77(4_Supplement). S3–5. 1 indexed citations

12.

Gendreau, Steven, Stephen Johnston, Peter Schmid, et al.. (2016). Abstract PD6-03: High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI). Cancer Research. 76(4_Supplement). PD6–3. 2 indexed citations

13.

Juric, Dejan, Cristina Saura, Andrés Cervantes, et al.. (2013). Abstract PD1-3: Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer. Cancer Research. 73(24_Supplement). PD1–3. 11 indexed citations

14.

Tolaney, SM, DA Yardley, Beverly Moy, et al.. (2013). Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Cancer Research. 73(24_Supplement). S1–4. 22 indexed citations

15.

Krop, IE, Julie Najita, Ingrid A. Mayer, et al.. (2011). The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003.. Journal of Clinical Oncology. 29(15_suppl). 528–528. 3 indexed citations

16.

Lin, NU, Ingrid A. Mayer, Julie Najita, et al.. (2011). TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology. 29(15_suppl). 527–527. 8 indexed citations

17.

Masciari, Serena, et al.. (2011). P1-09-03: Prevalence of Germline TP53 Mutations in Young Women with HER2−Positive Breast Cancer.. Cancer Research. 71(24_Supplement). P1–9. 1 indexed citations

18.

Chang, JC, et al.. (2010). Abstract P6-15-03: Phase Ib Trial of the Gamma Secretase Inhibitor (GSI), MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast Cancer. Cancer Research. 70(24_Supplement). P6–15. 2 indexed citations

19.

Krop, IE, Antonio C. Wolff, EP Winer, et al.. (2010). Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer. Cancer Research. 70(24_Supplement). P6–15. 8 indexed citations

20.

Krop, IE, Michele Kosh, Ivy Fearen, et al.. (2006). Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. Journal of Clinical Oncology. 24(18_suppl). 10574–10574. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact